Interferon Alfa Therapy Based on Th17 Profile in Membranous Nephropathy
NCT05941845
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
5
Enrollment
OTHER
Sponsor class
Conditions
Membranous Nephropathy
Interventions
DRUG:
Peginterferon Alfa-2A 180 MCG/ML Injectable Solution
Sponsor
Centre Hospitalier Universitaire de Nice